1. Introduction
scaly, injury or cutaneous inflammation, SD
PATHOPHYSIOLOGY, INFLAMMATORY SKIN DISEASE, FACIAL SEBORRHEIC DERMATITIS, SEBORRHEIC DERMATITIS
Facial seborrheic dermatitis (SD) is an inflammatory skin disease characterized by erythematous and scaly lesions on the skin with high sebaceous gland activity. The yeast Seborrheic dermatitis (SD) is a chronic inflammatory skin disease characterized by erythematous, scaling, and indurated papules and plaques on the face, scalp, and upper chest that affects up to 3% of the general population. While aberrant immunological responses are integral to its pathophysiology, these appear to be induced or exacerbated by multiple co-factors, such as an impaired barrier function, environmental factors, and microbial disturbances [Microbial involvement is characterized by the commensal yeast While it is hypothesized that the presence of Based on the high degree of microbial involvement, targeting both the fungal and bacterial microbiome through antimicrobial peptides (AMPs) is hypothesized to be a promising therapeutic option. AMPs are part of the skin’s innate immune response and are upregulated upon injury or cutaneous inflammation, providing an immediate host response against pathogens on the skin [Omiganan is an AMP that is analogous to indolicidin, a bovine member of the cathelicidin family. Its naturally occurring human counterpart LL-37 and derivatives have shown to be effective against selected Ultimately, the broader spectrum activity of AMPs such as omiganan could make these compounds a valuable therapeutic option for patients with SD that might render combination with corticosteroids unnecessary. In this study, we investigated the clinical efficacy, safety, tolerability, microbiological, and pharmacodynamic effects of omiganan 1.75% versus ketoconazole and a placebo in patients with mild-to-moderate facial SD. 